This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Tesaro, Inc.
Tesaro, Inc., a prominent biopharmaceutical company headquartered in the United States, is dedicated to advancing cancer treatment through innovative therapies. Founded in 2010, Tesaro has made significant strides in the oncology sector, particularly in the development of targeted therapies and immuno-oncology solutions. The company’s flagship product, Zejula (niraparib), is a groundbreaking treatment for ovarian cancer, distinguished by its ability to provide maintenance therapy for patients with recurrent disease. Tesaro's commitment to research and development has positioned it as a leader in the oncology market, with a focus on improving patient outcomes and quality of life. With a strong presence in North America and Europe, Tesaro continues to expand its portfolio, aiming to address unmet medical needs in cancer care. Its dedication to innovation and patient-centric solutions underscores its reputation as a key player in the biopharmaceutical industry.
DitchCarbon Score
How does Tesaro, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tesaro, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tesaro, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of GSK plc, which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its climate strategy, Tesaro, Inc. aligns with GSK plc's initiatives, which include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative. These initiatives aim to significantly reduce carbon emissions and transition to renewable energy sources. However, specific reduction targets or achievements for Tesaro, Inc. have not been disclosed. In summary, while Tesaro, Inc. does not provide its own emissions data, it is committed to climate action through its association with GSK plc, which sets the framework for its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tesaro, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
